Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Recursion Pharmaceuticals

< Previous 1 2 Next >
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Altitude Lab Startups Raise $154M in Capital
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion and Exscientia Shareholders Approve the Proposed Combination
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.